Thus, BRAF and FGFR1 mutations would be secondary driver events in the oncogenesis of these tumours and could give a proliferative advantage to the H3.3-K27M ancestral clone in a specific developmental window similarly to paediatric LGGs. The gene discussed is BRAF; the disease is neoplasm.